Chargement en cours...
Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
BACKGROUND: Inhibitors of proprotein convertase subtilisin kexin 9 are indicated in Canada for treatment of patients with familial hypercholesterolemia (FH). Classically, FH is considered to be a monogenic condition caused by rare pathogenic mutations; however, some patients have hypercholesterolemi...
Enregistré dans:
| Publié dans: | CJC Open |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7063626/ https://ncbi.nlm.nih.gov/pubmed/32159093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cjco.2019.02.005 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|